4IXV image
Deposition Date 2013-01-28
Release Date 2013-12-11
Last Version Date 2023-09-20
Entry Detail
PDB ID:
4IXV
Title:
Crystal structure of human Arginase-2 complexed with inhibitor 2d: {(5R)-5-amino-5-carboxy-5-[1-(4-chlorobenzyl)piperidin-4-yl]pentyl}(trihydroxy)borate(1-)
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.30 Å
R-Value Free:
0.23
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 42 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Arginase-2, mitochondrial
Gene (Uniprot):ARG2
Chain IDs:A, B, C
Chain Length:306
Number of Molecules:3
Biological Source:Homo sapiens
Primary Citation
Synthesis of quaternary alpha-amino acid-based arginase inhibitors via the Ugi reaction.
Bioorg.Med.Chem.Lett. 23 4837 4841 (2013)
PMID: 23886684 DOI: 10.1016/j.bmcl.2013.06.092

Abstact

The Ugi reaction has been successfully applied to the synthesis of novel arginase inhibitors. In an effort to decrease conformational flexibility of the previously reported series of 2-amino-6-boronohexanoic acid (ABH) analogs 1, we designed and synthesized a series of compounds, 2, in which a piperidine ring is linked directly to a quaternary amino acid center. Further improvement of in vitro activity was achieved by adding two carbon bridge in the piperidine ring, that is, tropane analogs 11. These improvements in activity are rationalized by X-ray crystallography analysis, which show that the tropane ring nitrogen atom moves into direct contact with Asp202 (arginase II numbering). The synthetic routes described here enabled the design of novel arginase inhibitors with improved potency and markedly different physico-chemical properties compared to ABH. Compound 11c represents the most in vitro active arginase inhibitor reported to date.

Legend

Protein

Chemical

Disease

Primary Citation of related structures